Top Lyme disease researchers from across the United States have collaborated on a new publication, Recent Progress in Lyme Disease and Remaining Challenges. In this review article, researchers summarize the state of Lyme over the past 5 years, addressing major scientific advances as well as identifying remaining challenges and needs. Topics covered in the publication […]
Peer Reviewed Articles
This section contains articles published in peer reviewed literature on Lyme and other tick-borne diseases, and on COVID 19. Articles are written by experts, and then several other experts in that field will review the article and send back comments/concerns to authors. Articles are sometimes changed/clarified to address the issues that are raised in order to be published. Not all info in peer-reviewed journals is reviewed such as editorials, letters, book reviews.
The LDA is providing the articles in this section for your information. The articles included express the findings and opinions of the authors and are not necessarily those of the the LDA.
In a study with lead author Dr. Brian Fallon, using Denmark’s National Patient Registry and Psychiatric Central Research Registry- including all persons living in Denmark from 1994-2016- the risk of mental disorders and suicides among all diagnosed with Lyme borreliosis was assessed. Those individuals with Lyme borreliosis had higher rates of any mental and affective […]
In a recent article published in Translational Vision Science and Technology, researchers found that contrast sensitivity impairment was associated with patients suffering from chronic lyme. According to the Online Medical Dictionary, contrast sensitivity is defined as “The ability to detect sharp boundaries (stimuli) and to detect slight changes in luminance at regions without distinct contours.” Investigators […]
Elizabeth L. Maloney, MD, reviews the US trial evidence on EM rashes, problems of the IDSA recommendations considering that evidence, and provides evidence-based patient-centered strategies for managing patients with EM. “The EM rash is the hallmark finding of early disease,” along with other symptoms. “In light of the physical and financial costs, identifying and promoting highly effective therapeutic interventions for US patients with erythema migrans (EM) rashes that return them to their pre-infection health status should be a priority.”
Data from a survey of respondents with self-reported tick bite encounters who concurrently reported a clinical or serological Lyme disease (LD) diagnosis from non-endemic states for Lyme disease was published in the journal Healthcare, June 21, 2021. Focusing on Texas, which due to large size, diverse climate, and ecological conditions, reflects environments that promote ticks, […]
A study published in PLOS Pathogens by Marisela M. Davis, et al. furthers understanding of the B. burgdorferi cell envelope and pathogenesis. The results highlight the plasticity of bacterial proteins and uncover some of the ways they may change how they perform a task despite no change in their basic biological function.
Frontiers in Neurology, 10 May 2021, published a study examining multiple molecular detection techniques to effectively identify Borrelia burgdorferi in the autopsy specimens of a patient with a history of neurocognitive disease. The individual was a post-mortem donor from the brain repository of the Lyme and Tick-Borne Diseases Research Center at the Columbia University Irving Medical Center.
The LDA has a long history of funding/supporting research projects that lead to real results. Below is the list of links to peer-reviewed articles that acknowledge LDA’s funding/support. Click on the publication link (or just scroll down to it) to see the authors, which authors LDA provided the funding for (green), and the abstract and […]
Ohio State University researchers have just published on their creation of nanobodies which target the protein that causes E. chaffeensis bacteria to be extremely infectious. It is thought that these nanobodies can be developed as a new or complementary therapy for human monocytic ehrlichiosis as well as other tick-borne diseases that are caused by intracellular infections, infections that can be fatal if left untreated or undertreated.